Dr. Shain Discusses Emerging Agents in Multiple Myeloma

Kenneth H. Shain, MD, PhD
Published: Friday, May 26, 2017



Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.

Oprozomib, an oral agent, is an irreversible proteasome inhibitor that has shown good activity in highly refractory patients.

Additionally, there is marizomib, another proteasome inhibitor that is being looked at alone and in combinations. It still requires further study—but it is something exciting that is on the horizon, says Shain.
 


Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.

Oprozomib, an oral agent, is an irreversible proteasome inhibitor that has shown good activity in highly refractory patients.

Additionally, there is marizomib, another proteasome inhibitor that is being looked at alone and in combinations. It still requires further study—but it is something exciting that is on the horizon, says Shain.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x